New! View global litigation for patent families

US20010044620A1 - Microfabricated injectable drug delivery system - Google Patents

Microfabricated injectable drug delivery system Download PDF

Info

Publication number
US20010044620A1
US20010044620A1 US09795384 US79538401A US2001044620A1 US 20010044620 A1 US20010044620 A1 US 20010044620A1 US 09795384 US09795384 US 09795384 US 79538401 A US79538401 A US 79538401A US 2001044620 A1 US2001044620 A1 US 2001044620A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
drug
delivery
device
valves
osmotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09795384
Other versions
US6454759B2 (en )
Inventor
Peter Krulevitch
Amy Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lawrence Livermore National Security LLC
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0097Micromachined devices; Microelectromechanical systems [MEMS]; Devices obtained by lithographic treatment of silicon; Devices comprising chips
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis

Abstract

A microfabricated, fully integrated drug delivery system capable of secreting controlled dosages of multiple drugs over long periods of time (up to a year). The device includes a long and narrow shaped implant with a sharp leading edge for implantation under the skin of a human in a manner analogous to a sliver. The implant includes: 1) one or more micromachined, integrated, zero power, high and constant pressure generating osmotic engine; 2) low power addressable one-shot shape memory polymer (SMP) valves for switching on the osmotic engine, and for opening drug outlet ports; 3) microfabricated polymer pistons for isolating the pressure source from drug-filled microchannels; 4) multiple drug/multiple dosage capacity, and 5) anisotropically-etched, atomically-sharp silicon leading edge for penetrating the skin during implantation. The device includes an externally mounted controller for controlling on-board electronics which activates the SMP microvalves, etc. of the implant.

Description

    RELATED APPLICATION
  • [0001]
    The application relates to U.S. Provisional Application No. 60/185,527 filed Feb. 28, 2000, and claims priority thereof.
  • [0002] The United States Government has rights in this invention pursuant to Contract No. W-7405-ENG-48 between the United States Department of Energy and the University of California for the operation of Lawrence Livermore National Laboratory.
  • BACKGROUND OF THE INVENTION
  • [0003]
    The present invention relates to drug delivery systems, particularly to implantable drug delivery systems, and more particularly to an implantable, microfabricated, fully integrated drug delivery system capable of secreting controlled dosages of multiple or single drugs over long periods of time.
  • [0004]
    Historically, pharmaceutically active agents have been chosen based on biological activity, with absorption, efficacy, and side effect profiles determined by metabolic process. The effectiveness of the therapeutic agent can be enhanced by sophisticated drug delivery systems that actively control the delivery rate and site of drug action.
  • [0005]
    Alza Corporation, Palo Alto, Calif., has developed a drug delivery system that uses osmotic pressure to infuse drugs, as exemplified by U.S. Pat. No. 5,151,093 issue Sep. 29, 1992. Also Alza Corporation has developed an implantable drug delivery system using osmotic pressure which basically consists of a titanium tube having a water-permeable membrane on one end, and containing a salt pellet, piston, and drug, with an orifice on the opposite end. Water diffuses through the membrane and creates a high concentration NaCl solution by dissolving the salt pellet. Additional water is driven into the device due to the concentration gradient across the membrane, generating osmotic pressures as great as 3000 psi. The pressure pushes on the piston and forces the drug through the orifice at a constant rate. The implantation is performed using a trocar (large syringe) by a physician, after which drug delivery is automatic, eliminating the rests of patients forgetting to take prescribed medication. For infections diseases such as hepatitis, implants such as these will avoid the creation of drug-resistant strains by patients who neglect to complete their prescribed drug schedule. In addition these systems will aid individuals in long-term health management such as hormone therapy.
  • [0006]
    The prior implantable systems can be improved considerably by reducing the size and adding flow control to enable variable and programmable dosage profiles. This invention allows for delivery of multiple drugs over a period of time and can be programmed or externally controlled. And can be powered by a number of means: 1.) Osmosis; 2.) Thermopneumatic; 3.) Thermal bimorphs; 4.)Shape memory films; 5.) Piezoelectric bimorphs. The drug delivery system having multiple channels to allow for controlled delivery profiles, precise drug metering, and the ability to independently control delivery of several drugs or drug combinations with the same device. The miniature device of the present invention can be implanted prophylactically and lie dormant until activated in response to a therapeutic need by an externally located controller via implanted electronics. Thus, the present invention enables the administering of any drug (vaccines, booster, hormones, antibiotics, etc.) at either discrete time intervals or at a specified rate, such as to soldiers in a controlled manner or in response to a chemical/biological warfare attack.
  • SUMMARY OF THE INVENTION
  • [0007]
    It is an object of the present invention to provide a microfabricated in injectable drug delivery system.
  • [0008]
    a further object of the invention is to provide an implantable drug delivery system which may be controlled externally.
  • [0009]
    a further object of the invention is to provide an implantable, osmotic engine-based drug delivery system, which utilizes polymer pistons for isolating the pressure source from drug-filled microchannels.
  • [0010]
    Another object of the invention is to provide a micromachined implantable, osmotically driven drug delivery system utilizing shape memory polymer valves for controlling the osmotic engine and drug outlet ports.
  • [0011]
    Another object of the invention is to provide an implantable drug delivery device which includes an anisotropically-etched, atomically-sharp silicon leading edge for penetrating the skin during implantation.
  • [0012]
    Another object of the invention is to provide a drug delivery device of a stacked modular disc-shaped design incorporating membranes for displacing the drugs.
  • [0013]
    Another object of the invention is to provide a pumping and valving arrangement that could also be used to deliver samples, reagents, and other fluids in ex-vivo microfluidic-based medical diagnostic instruments.
  • [0014]
    Other objects and advantages of the present invention will become apparent from the following description and accompanying drawings. Basically the invention involves a microfabricated injectable drug delivery system which includes an inplantable, osmotically driven device controlled by shape memory polymer valves which can be activated by an external controller. The implantable osmotic driven device utilizes microfabricated polymer pistons for isolating the pressure source from drug-filled microchannel (an equivalent to microscale syringes). The implantable device is scalable to accommodate a broad range of desired drugs and/or drug volumes. Potential applications for the invention include response to detection of biological or chemical warfare threats, regulated delivery of vaccines or boosters (e.g. anthrax—9 boosters over 18 mos.), hormone therapy, on demand pain medication and insulin delivery for diabetes management. A demonstration embodiment of a silicon and glass-based device includes an array of four parallel osmotic pumps fabricated on a single 4 mm×1 mm×25 mm member.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0015]
    The accompanying drawings, which are incorporated into and form a part of the disclosure, illustrate embodiments of the invention and fabrication method for the control valves thereof and, together with the description, serve to explain the principles of the invention.
  • [0016]
    [0016]FIG. 1 illustrates an overall view with an enlarged section of an implanted drug pump activated by a threat detection.
  • [0017]
    [0017]FIG. 2, illustrates an embodiment of a microfabricated, implantable, multi-channel drug delivery device made in accordance with the present invention.
  • [0018]
    [0018]FIG. 3 illustrates an embodiment of a stacked modular disc-shaped design incorporating membranes for displacing the drugs.
  • [0019]
    FIGS. 4A-4C illustrate the fabrication of a polymer micropiston for driving the drugs.
  • [0020]
    [0020]FIG. 5 illustrates the loading of microchannels with fluid after fabricating the osmotic engine.
  • [0021]
    [0021]FIG. 6A-6G illustrates a shape memory polymer valve fabrication process sequence.
  • [0022]
    FIGS. 7A-7B set forth a block diagram of controller and on-board electronics for the device of FIG. 2.
  • DETAILED DESCRIPTION OF THE INVENTION
  • [0023]
    The present invention is directed to a microfabricated injectable drug delivery system. The system enables the remotely controlled delivery of therapeutic agents (such as broad-spectrum antibiotics, vaccines or neuroprotective agents) in preparation for, and response to, biological and chemical (BN/CW) threats. The invention is a self-contained biofluidic microsystem with on-board control electronics capable of controlled delivery of therapeutic substantances to an individual. The system includes a miniature device to be implanted prophylactically and lie dormant until activated in response to a therapeutic need. The device can be activated on demand in response to a threat, or it can be programmed to deliver multiple doses according to a pre-determined schedule, such as for vaccine boosters. The system includes an interface to the implanted device, which is a hand-held or externally worn control unit, which also inductively couples electromagnetic power into the implanted device for the on-board electronics. Commands may be delivered to the control unit by radio communication. The system will function over periods ranging from months to years. The fully integrated delivery system will be capable of dispensing controlled dosages of multiple therapeutics.
  • [0024]
    The heart of the system is an osmotic pressure source that uses energy stored I the form of a concentration potential to generate thousands of psi working pressure. A solute-filled chamber is exposed to a fluid across a semipermeable membrane. Water diffuses through the membrane to balance the concentration of dissolved solute, and in the process raises the pressure within the osmotic chamber. The pressure will displace a polymeric micro-piston, which will eject a stored therapeutic agent. Multiple osmotic micropumps can be microfabricated in an array to form what is called an “osmotic engine”. Fluid control of each individual chamber in the array will be achieved with temperature controlled shape memory polymer valves activated by remote electronics. The osmotic engine chambers can be loaded with different agents for delivery of multiple therapeutics. Alternatively the chambers can be loaded with discrete does of a single therapeutic. Time of release and rate of agent delivery is pre-programmable in either application.
  • [0025]
    The drug delivery system of the present invention includes: 1) on-chip self-powered osmotic engine/fluidic manifolds; 2) integrated polymeric micropistons for delivering fluids (drugs); 3) addressable arrays of low power microfabricated shape memory polymer fluid control elements; 4) energy harvesting of extracellular fluid to drive osmotic pressure generation; and 5) RF-powered electronics for remote control and programming. The invention involves the combining of micro pumps, shape memory polymer valves, polymeric micropistons for delivering fluids, on-chip or on-board electronics, and an externally located controller/activator.
  • [0026]
    Referring now to the drawings, FIG. 1 illustrates an application of the present invention wherein a human being wearing an implanted drug pump and an external controller is provided with drugs in response to a threat detection via a command relay. As shown a drug delivery system 10 which includes an implanted pump 11 and an external controller 12 on an arm 13 of a human body 14 is activated by a threat detection 15 via a command relay 16, whereby the body is protected from exposure to biological/chemical materials by injection of an appropriate anti-material drug via the implanted pump.
  • [0027]
    [0027]FIG. 2 illustrates an embodiment of an implanted pump 11 of FIG. 1 for the microfabricated drug delivery system of this invention. As shown, a glass substrate or member with drilled or etched holes is bonded to a silicon wafer or substrate with etched microchannels. The silicon has an anisotropically etched sharp leading edge for penetrating the skin of a user. This eliminates the need for an incision or a trocar for implanting the device. The silicon and glass members are bonded together, forming a hermetic seal. It is possible to seal the electronics within the two substrates to protect them from the body. The device of FIG. 2 also could be made from polymeric or other materials. Shape memory polymer (SMP) valve arrays control fluid flow into and out of the device. The polymer may be micromolded such that it contains small holes or pores that open upon heating. Alternatively the valve may rely on control of the inherent material porosity by heating or cooling for controlling fluid flow. Silicon or glass substrates with etched features serve as the mold for the polymeric valves. One possible method for heating the valves locally is to use embedded resistive heater arrays. Once open, the SMP valves remain open, and thus are called “one-shot” valves. Pre-programmed or telemetry-equipped electronics control the operation of the valves. The outlet valves could also be pressure activated such as a polymer membrane with a slit that isolates the drug from the body until pressure from the osmotic engine forces the drug to leak out of the microchannel. The polymer pistons are designed so as not to leak any fluid there passed in either direction.
  • [0028]
    The microchannels within the implant or device contain pistons or plugs that isolate the drug reservoir from the NaCl (or other osmotic salt). These plugs are injected or inserted into the channel and may be made from polymers, rubbers, foams, or other materials. To form a seal within the microchannels, expanding polymers or polymers that swell when exposed to fluids may be used. Selectively opening the inlet valves allows extra cellular body fluid to permeate the NaCl, thus creating an osmotically induced pressure across the valve membrane. When the outlet valve to the same microchannel is opened, the pressure drives the piston, and the drug is delivered into the body at a rate determined by the induced pressure and the pore or orifice size of the outlet valve. Other valves can be sequentially opened at designated times to produce the desired drug delivery profile.
  • [0029]
    As seen in FIG. 2, the implant or device, generally indicated at 20 comprises a silicon substrate or member 21 and a glass substrate or member 22 bonded together, with the silicon substrate 21 have a sharp lead edge 23 for device insertion (penetration under the skin). The silicon substrate 21 is provided with a plurality of mnicrochannels 24, five in this embodiment but with only four being drug filled as indicated at 25. Microchannels 24 also contain a plurality of polymer plugs or pistons 26 and contain a quantity of NaCl, with the polymer pistons design to prevent leakage between the NaCl filled section and the drug-filled section of microchannels 24. The glass substrate 22 is provided with an array of inlet openings 27 and an array of outlet openings 28, each opening array be located at and in communication with ends of microchannels 24. Mounted on the glass substrate 22 is a layer of polymer material 29 having an array of shape memory polymer (SMP) inlet valves indicated at 30 therein which align with inlet openings 27; and a layer of polymer material 31 having an array of shape memory polymer (SMP) outlet valves indicated at 32 which align with outlet opening 28. Also mounted on glass substrate 22 is a layer 33 of material, composed of a silicon cup on which is mounted telemetry and control circuitry indicated at 34 (see FIG. 7B). The NaCl 27 in microchannels 24 could be replaced with material such as KCL, or any salt material suitable for generating sufficient osmotic pressure. FIG. 3 shows an alternative design for the implantable device of FIG. 2, and uses a stacked modular approach with two microfabricated valves, a water permeable membrane, an NaCl reservoir, a super elastic NiTi membrane, a drug reservoir and an outlet control valve. When the inlet valve is opened, interstitial fluid diffuses across the water permeable membrane and permeates the NaCl, creating the osmotic pressure. This pressure causes the super elastic NiTi membrane to bulge, displacing drug from the drug reservoir through the outlet orifice. The outlet valve regulates flow of the drug into the body, super elastic NiTi films enable exceptionally large displacements, and consequently allow for increased drug volume delivery.
  • [0030]
    As shown in FIG. 3, the stacked modular embodiment comprises a pair of microfabrication inlet and outlet control valves 40 and 41, an inlet regulator 42, a water permeable membrane 43, an NaCl reservoir 44, a super elastic NiTi membrane 45, a drug reservoir 46, and an outlet regulator 47.
  • [0031]
    Microfabrication techniques are available to construct the various components or sections of the implant or device of FIG. 2. Bulk etching of silicon and glass is a common technique for micromachining channels. Here, it is critical to have a liquid-tight seal across the piston or plug to ensure accurate dose delivery. Factors that influence sliding and sealing characteristics of the piston include the materials of the piston and the microchannels, channel cross-section, channel roughness, piston length, and applied pressure. Tests have shown that channels can be formed by isotropically etching resulting in microchannels with rounded corners.
  • [0032]
    The piston or plug is most readily moved through a microchannel having a configuration corresponding to the external configuration of the plug. Generally, a circular shaped microchannel and corresponding configured plug is preferable, although other shapes having rounded corners are acceptable. Recently a process has been developed for producing circular microchannels in glass, and is described and claimed in copending U.S. application Ser. No. 09/(IL-10581), filed ______ 2001, entitled “Method for Producting Microchannels Having Circular Cross-Sections in Glass”, assigned to the same assigned. In that method a substrate having etched microchannels is bonded to a top plate and then annealed to allow surface tension forces and diffusional effects to lower the overall energy of the microchannels by transforming the cross-section to a circular shape. Another approach to the formation of circular cross-section micro-channels involves embedding of wires or round members of a desired diameter into a (PDMS) substrate, and then pulling out the wire or member following the curing process which creates perfectly circular channels. This results in a flexible microfluidics device with perfectly circular and smooth channels that can be applied in various biomedical microdevice and other microsystems. This process is both time and cost effective due to its simplicity and quick turn around time. The channels can be fabricated in an hour and the cost is tremendously reduced since no silicon is used. An example of a channel made using this technique has been shown in an SEM cross-sectional image, and small hard balls have been loaded into these soft PDMS channels and have been driven with an external pneumatic actuator (syringe). Fluid was successfully pumped using the microsyringe, with the balls forming effective seals against the PDMS microchannels.
  • [0033]
    Using the microchannel itself as a precision mold to ensure consistent sealing and sliding characteristics, silicon micropistons have been produced. FIGS. 4A-4C illustrate the micropiston fabrication process. First, a thermoplastic polymer is deposited and patterned on the osmotic engine substrate, as shown in FIG. 4A. Next, heating the substrate causes the polymer to liquefy, and capillary forces pull the polymer into the microchannel, which acts as a precision mold for the micropiston, as shown in FIG. 4B. Finally, when pressure is applied to the microchannel, the micropiston slides within the channel, shearing off a portion that remains to seal the polymer via, as seen in FIG. 4C.
  • [0034]
    After fabricating the osmotic engine, the drugs to be delivered by the system are introduced through fluid injection ports, as shown in FIG. 5. After filling, the ports are sealed. Multiple ports can be filled simultaneously with various fluids using robotic feeders such as those used to interface with microtiter plates.
  • [0035]
    Two basic approaches to valve structure have been considered. The first can be considered as passive where SMP simply pinches off access to the microosmotic pump actuator. A second approach involves valves that exploit control of SMP porosity.
  • [0036]
    In the first approach, the valves will be closed in the deformed, hard state of the SMP material. Remotely addressable on-board electronics will heat selected valves, causing them to return to the remembered, open state. In the second approach, the osmotic engine will be regulated using individually addressable controlled permeability shape memory polymer microvalves. When sealed, the osmotic solute inside the device will be isolated from the extra cellular fluid. Heating selected polymer patches using addressable embedded resistive heaters will cause pores within the SMP to open, allowing water to diffuse through the polymer and hydrating the osmotic solute. The shape memory polymer controlled-permeability valves may be fabricated as illustrated in FIGS. 6A-6G. The batch process will enable multiple microvalves to be fabricated and sealed simultaneously on the same substrate. The SMP valve fabrication process sequence is as follows:
  • [0037]
    1. pattern resistive heater over inlet port, see FIG. 6A;
  • [0038]
    2. deposit shape memory polymer, see FIG. 6B;
  • [0039]
    3. pattern pores into SMP, see FIG. 6C;
  • [0040]
    4. heat SMP and mate with mold, see FIG. 6D;
  • [0041]
    5. mold SMN, see FIG. 6E;
  • [0042]
    6. remove mold—pores are sealed, see FIG. 6F; and
  • [0043]
    7. heat SMP to open pores, see FIG. 6G.
  • [0044]
    The osmotic pump chamber has two valves or two arrays of valves. The input valve or valve array will permit extra cellular fluid to enter a specific (or all) osmotic pump channel. The output valve or valve array will activate release of the drug in the associated reservoir or reservoirs. Multiple reservoirs can be actuated independently, or simultaneously, such that a liquid or drug can be delivered at specific times, or multiple types of drugs can be delivered.
  • [0045]
    Addressable integrated heaters will be used to actuate the valves. The heat necessary to surpass the SMP glass transition temperature can be supplied in a variety of ways. For example, integrated thermal elements consisting of serpentine coils of conducting thin films can be used. Possible films include platinum and polysilicon and will be in contact with the SMP to provide efficient thermal transfer. The shape memory polymers can also be embedded with conducting particles to improve uniform heating. Thin film conductors can be deposited, as in FIG. 6B, prior to the SMP materials. Subsequent molding deposition of SMP will yield a suspended thin film layer above the SMP layer.
  • [0046]
    [0046]FIG. 7A shows the block diagram of the control unit. It is activated by means of a keypress on the keypad. The user will be able to either activate one or more valves or query the on-board electronics as to which valves have been already been activated. The controller will be constructed in a plastic enclosure small enough to be handheld. The circuits will be of hybrid construction using surface mount components. If necessary, an ASIC will be fabricated in the second and third generation versions. A stored program in the ROM controls the operation of the microprocessor. The microprofessor either sends the appropriate valve opening code or status query code to the Modulator or receives response form the Demodulator to a prior status query. The status query response form the on-board electronics will be in the form of coded time-varying power demands imposed on the controller by the on-board electronics. These demands will result in the voltage amplitude at the antenna varying as a function of time. The demodulator will convert the coded time variations to baseband where they can be interpreted by the microprocessor.
  • [0047]
    The transmission of signals and power over the RF link will be in the 1-10 MHz range so that the size of the antennas and other components can be minimized. During the entire time the control unit is activated, a large amplitude carrier signal will be continuously sent to the on-board electronics to provide the needed power. Information and commands will be encoded as amplitude modulation on the carrier.
  • [0048]
    The signal from the on-board antenna will be full-wave rectified, filtered, and regulated by a voltage regulator to provide the needed dc voltages for the rest of the on-board electronics. During the short time intervals when the carrier amplitude is low because of signal modulation or when the on-board unit is sending status information to the controller, power will be supplied from stored energy in the rectifier filter capacitor. The amount of energy drain during these short time intervals will only be a small fraction of the stored energy.
  • [0049]
    The block diagram of the on-board pump array electronics is shown in FIG. 7B. When the on-board antenna receives a signal from the controller, the power conditioning circuit establishes the voltages needed to power the rest of the on-board electronics. The unit begins operation in a default state of receiving information from the controller. After a handshaking protocol is completed, the unit is ready to receive commands. As information is received, the signal is demodulated, decoded by the logic and the logic then issues appropriate commands to either open valves or query their status. If a status query is issued, the response is encoded by the logic and sent to the load switch. The load switch which activates a dummy load in a coded time-varying manner in order to vary the power demanded by the chip from the control unit.
  • [0050]
    Indication of valve status will be accomplished by a passive indictor read by the logic, which does not require any electrical power when the control unit is off. Several possibilities exist for the status indictor including a fusible link that is burnt open when the valve is activated or a EPROM like memory cell that stores a logic “1” when the valve is activated.
  • [0051]
    The antennas for the electronics will be multi-turn pancake coils with a diameter of approximately 1-cm for the coil connected to the controller and approximately 3 mm for the coil on the pump array substrate. Preliminary calculations indicate that ten turns for the controller coil and 50-100 turns for the on-board coil will generate 5-10 volts dc o the pump array wafer at a power level of approximately 10 milliwatts. The first generation coils will be handwound. We will investigate fabricating the second and third generation coils using photolithography and electroplating.
  • [0052]
    It has thus been shown that the present invention provides a microfabricated, fully integrated drug delivery system capable of secreting controlled dosages of multiple drugs over long periods of time. The implantable drug delivery system of this invention enables administering vaccines, boosters, hormones, or antibiotics in a controlled manner, and is particularly useful in response to a chemical/biological warfare attack. The invention enables controlled drug delivery to patients who might forget to take their medication. As an example, the device would add great convenience to hepatitis and HIV infected patients or individuals ho require hormone therapy who must periodically take drugs over a long period of time.
  • [0053]
    While particular embodiments, materials, parameters, etc. have been described or illustrated to exemplify and teach the principles of the invention, such are not intended to be limiting. Modifications and changes may become apparent to those skilled in the art, and it is intended that the invention be limited only by the scope of the appended claims.

Claims (19)

    The invention claimed is:
  1. 1. A system for injectable drug delivery, comprising:
    an implantable device containing in at least one drug to be delivered by osmotic pressure,
    valves in said device for at least controlling generation of said osmotic pressure, and
    an externally located controller for activating said valves.
  2. 2. The system of
    claim 1
    , wherein said implantable device comprises a housing having at least one microchannel in said housing, said at least one drug to be delivered being located in a section of said at least one microchannel.
  3. 3. The system of
    claim 2
    , wherein said osmotic pressure is generated by an osmotic device located in said it least one microchannel.
  4. 4. The system of
    claim 3
    , additionally including a piston located in said at least one microchannel intermediate said osmotic device and said at least one drug to be delivered.
  5. 5. The system of
    claim 2
    , wherein said housing includes a sharp leading edge to assist in implantation thereof.
  6. 6. The system of
    claim 5
    , wherein said housing is composed of a silicon member and a glass member, said silicon member containing said at least one microchannel in a surface adjacent said glass member.
  7. 7. The system of
    claim 6
    , wherein said valves are mounted to control opening in said glass member, said openings being in fluid communication with said at least one microchannel.
  8. 8. The system of
    claim 7
    , additionally including at least electronics for activating said valves, said electronics be constructed to receive activation signals from said externally located controller.
  9. 9. The system of
    claim 8
    , wherein said electronics are mounted on said glass member.
  10. 10. The system of claims 1, wherein said externally located controller is constructed to be activated by detection of a chemical/biological material.
  11. 11. The system of
    claim 1
    , wherein said valves include shape memory polymer material, and wherein said implantable device includes a heater for said shape memory polymer material for activating said valves.
  12. 12. The system of
    claim 1
    , wherein said valves include a porous polymeric material, and wherein said implantable device includes a heater for said porous polymeric material for changing the porousity of the polymeric material.
  13. 13. The system of
    claim 2
    , wherein said housing includes a plurality of microchannels, each microchannel containing a drug and on osmotic device for dispensing the drug from said microchannel when said valves are activated.
  14. 14. In an implantable, osmotic driven drug delivery device, the improvement comprising:
    a plurality of microchannels located in said device,
    each microchannel having a drug-filled section,
    each microchannel having an osmotic pressure generating section,
    each microchannel having a piston located intermediate said osmotic pressure generating section and said drug-filled section,
    said piston being constructed to prevent fluid leakage therepast,
    valve means for controlling activation of said osmotic pressure generating section, and valve means for controlling discharge from said drug-filled section.
  15. 15. The improvement of
    claim 14
    , wherein said valve means comprises shape memory polymer valves.
  16. 16. The improvement of
    claim 15
    , additionally including means for controlling activation of said shape memory polymer valves.
  17. 17. The improvement of
    claim 16
    , wherein said microchannels are located in a silicon member, and wherein said silicon member includes a sharp leading edge for assisting in implanting said device.
  18. 18. The improvement of
    claim 17
    , additionally including a glass member having a plurality of openings are aligned with each of said microchannels.
  19. 19. The improvement of
    claim 18
    , wherein said valve means comprises a shape memory polymer valve for each of said openings.
US09795384 2000-02-28 2001-02-28 Microfabricated injectable drug delivery system Expired - Fee Related US6454759B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US18552700 true 2000-02-28 2000-02-28
US09795384 US6454759B2 (en) 2000-02-28 2001-02-28 Microfabricated injectable drug delivery system

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09795384 US6454759B2 (en) 2000-02-28 2001-02-28 Microfabricated injectable drug delivery system

Publications (2)

Publication Number Publication Date
US20010044620A1 true true US20010044620A1 (en) 2001-11-22
US6454759B2 US6454759B2 (en) 2002-09-24

Family

ID=26881219

Family Applications (1)

Application Number Title Priority Date Filing Date
US09795384 Expired - Fee Related US6454759B2 (en) 2000-02-28 2001-02-28 Microfabricated injectable drug delivery system

Country Status (1)

Country Link
US (1) US6454759B2 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020169386A1 (en) * 2000-11-13 2002-11-14 Johnson Robert L. Real-time biological-chemical-physical sensitivity and irritation onset neuro sensory (BIOCAPSIONS) biofeedback monitor
EP1435920A1 (en) * 2001-09-19 2004-07-14 Durect Corporation Flow regulator
EP1481705A1 (en) * 2003-05-27 2004-12-01 C.R.F. Societa' Consortile per Azioni A radiofrequency-controlled device for release / sampling of substances
US20050197649A1 (en) * 2004-03-02 2005-09-08 Medical Research Products-A, Inc. Method and apparatus for automatically modifying delivery profile of drug delivery system
WO2006077528A2 (en) * 2005-01-18 2006-07-27 Koninklijke Philips Electronics, N.V. Electronically controlled capsule
US20080171342A1 (en) * 2006-07-17 2008-07-17 Industrial Technology Research Institute Fluidic devices and controlling methods thereof
US20090005727A1 (en) * 2006-03-09 2009-01-01 Searete Llc Acoustically controlled substance delivery device
ES2319147A1 (en) * 2007-03-30 2009-05-04 Universidad Politecnica De Madrid Microsystem TELEOPERATED with active chambers for chemical analysis.
US20090162249A1 (en) * 2006-03-09 2009-06-25 Searete Llc Acoustically controlled reaction device
US20090259214A1 (en) * 2008-04-09 2009-10-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Agent delivery device
US20100030185A1 (en) * 2006-01-18 2010-02-04 Searete Llc Remote controller for substance delivery system
US20100076415A1 (en) * 2005-11-09 2010-03-25 Searete Llc Remote control of substance delivery system
US20110172525A1 (en) * 2008-12-05 2011-07-14 Neer Charles S Inductively Coupled Injector Faceplate
GB2446099B (en) * 2005-11-09 2011-11-02 Searete Llc Osmotic pump with remotely controlled osmotic flow rate
GB2462779B (en) * 2007-05-25 2012-03-07 Searete Llc Injectable controlled release fluid delivery system
US8529551B2 (en) 2005-11-09 2013-09-10 The Invention Science Fund I, Llc Acoustically controlled substance delivery device
US8568388B2 (en) 2005-11-09 2013-10-29 The Invention Science Fund I, Llc Remote controlled in situ reaction device
US8906000B2 (en) 2005-11-09 2014-12-09 The Invention Science Fund I, Llc Injectable controlled release fluid delivery system
US9067047B2 (en) 2005-11-09 2015-06-30 The Invention Science Fund I, Llc Injectable controlled release fluid delivery system
JP2016512992A (en) * 2013-02-28 2016-05-12 マイクロチップス バイオテック,インコーポレイテッド Implantable medical devices for minimally invasive insertion

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682521B2 (en) 2000-03-23 2004-01-27 Dennis N. Petrakis Temperature activated systems
US20020114739A1 (en) * 2000-12-26 2002-08-22 Weigl Bernard H. Microfluidic cartridge with integrated electronics
US7083593B2 (en) * 2001-04-18 2006-08-01 Advanced Bionics Corporation Programmable implantable pump with accessory reservoirs and multiple independent lumen catheter
US6723086B2 (en) * 2001-05-07 2004-04-20 Logiq Wireless Solutions, Inc. Remote controlled transdermal medication delivery device
US6888532B2 (en) * 2001-11-30 2005-05-03 Palmone, Inc. Automatic orientation-based user interface for an ambiguous handheld device
US8309057B2 (en) * 2005-06-10 2012-11-13 The Invention Science Fund I, Llc Methods for elevating neurotrophic agents
GB2446096B (en) * 2005-11-09 2012-01-11 Searete Llc Accoustically controlled reaction device
JP5076167B2 (en) * 2005-11-09 2012-11-21 ザ インベンション サイエンス ファンド アイ,エルエルシー Osmotic pump with the osmotic pressure generated to be remotely controlled
WO2007122552A3 (en) * 2006-04-26 2008-01-31 Koninkl Philips Electronics Nv Device for the controlled release of a substance and method of releasing a substance
US20070260174A1 (en) * 2006-05-05 2007-11-08 Searete Llc Detecting a failure to maintain a regimen
CN101460213A (en) * 2006-06-02 2009-06-17 皇家飞利浦电子股份有限公司 Device for the controlled release of a substance
US8632034B2 (en) * 2007-03-23 2014-01-21 The Boeing Company Self-powered dimmable windows with integrated controls
US20080234893A1 (en) * 2007-03-23 2008-09-25 The Boeing Company Window control system
US8292228B2 (en) * 2007-03-30 2012-10-23 The Boeing Company Control system for dimmable windows
US8160695B2 (en) 2007-12-05 2012-04-17 The Invention Science Fund I, Llc System for chemical modulation of neural activity
US8195287B2 (en) 2007-12-05 2012-06-05 The Invention Science Fund I, Llc Method for electrical modulation of neural conduction
US8180446B2 (en) 2007-12-05 2012-05-15 The Invention Science Fund I, Llc Method and system for cyclical neural modulation based on activity state
US8165669B2 (en) 2007-12-05 2012-04-24 The Invention Science Fund I, Llc System for magnetic modulation of neural conduction
US8170658B2 (en) 2007-12-05 2012-05-01 The Invention Science Fund I, Llc System for electrical modulation of neural conduction
US8180447B2 (en) 2007-12-05 2012-05-15 The Invention Science Fund I, Llc Method for reversible chemical modulation of neural activity
US8170660B2 (en) 2007-12-05 2012-05-01 The Invention Science Fund I, Llc System for thermal modulation of neural activity
US8165668B2 (en) 2007-12-05 2012-04-24 The Invention Science Fund I, Llc Method for magnetic modulation of neural conduction
US8022843B2 (en) * 2008-03-31 2011-09-20 The Boeing Company Wireless aircraft sensor network
US20090259176A1 (en) * 2008-04-09 2009-10-15 Los Gatos Research, Inc. Transdermal patch system
US20100061976A1 (en) * 2008-07-24 2010-03-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject
US20100022494A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method, device, and kit for maintaining physiological levels of steroid hormone in a subject
US20100022497A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on APOE allelic profile of a mammalian subject
US20100022991A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System and device for maintaining physiological levels of steroid hormone in a subject
US8246565B2 (en) 2009-02-25 2012-08-21 The Invention Science Fund I, Llc Device for passively removing a target component from blood or lymph of a vertebrate subject
US8317737B2 (en) * 2009-02-25 2012-11-27 The Invention Science Fund I, Llc Device for actively removing a target component from blood or lymph of a vertebrate subject
US8986337B2 (en) 2012-02-24 2015-03-24 Elwha Llc Devices, systems, and methods to control stomach volume
US9399216B2 (en) * 2013-12-30 2016-07-26 General Electric Company Fluid transport in microfluidic applications with sensors for detecting fluid presence and pressure
WO2017004576A1 (en) * 2015-07-02 2017-01-05 The Board Of Trustees Of The University Of Illinois Wireless optofluidic systems for programmable in vivo pharmacology and optogenetics

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2928477C3 (en) * 1979-07-14 1982-04-15 Battelle-Institut E.V., 6000 Frankfurt, De
US4326524A (en) * 1980-09-30 1982-04-27 Minnesota Mining And Manufacturing Company Solid dose ballistic projectile
US4585652A (en) * 1984-11-19 1986-04-29 Regents Of The University Of Minnesota Electrochemical controlled release drug delivery system
US4838862A (en) * 1986-08-04 1989-06-13 Pharmetrix Corp. Portable controlled release osmotic infusion device
US4976966A (en) * 1988-12-29 1990-12-11 Alza Corporation Delayed release osmotically driven fluid dispenser
US5170801A (en) * 1990-10-02 1992-12-15 Glaxo Inc. Medical capsule device actuated by radio-frequency (rf) signal
US5151093A (en) 1990-10-29 1992-09-29 Alza Corporation Osmotically driven syringe with programmable agent delivery
US5217449A (en) * 1990-12-11 1993-06-08 Miyarisan Kabushiki Kaisha Medical capsule and apparatus for activating the same
US5290240A (en) * 1993-02-03 1994-03-01 Pharmetrix Corporation Electrochemical controlled dispensing assembly and method for selective and controlled delivery of a dispensing fluid
US5837276A (en) * 1994-09-02 1998-11-17 Delab Apparatus for the delivery of elongate solid drug compositions
US5874214A (en) * 1995-04-25 1999-02-23 Irori Remotely programmable matrices with memories
DE69837894D1 (en) * 1997-03-24 2007-07-19 Alza Corp An implantable delivery device having a self-aligned outlet opening
US6059736A (en) * 1998-02-24 2000-05-09 Tapper; Robert Sensor controlled analysis and therapeutic delivery system
US6349740B1 (en) * 1999-04-08 2002-02-26 Abbott Laboratories Monolithic high performance miniature flow control unit

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020169386A1 (en) * 2000-11-13 2002-11-14 Johnson Robert L. Real-time biological-chemical-physical sensitivity and irritation onset neuro sensory (BIOCAPSIONS) biofeedback monitor
EP1435920A1 (en) * 2001-09-19 2004-07-14 Durect Corporation Flow regulator
EP1435920A4 (en) * 2001-09-19 2007-01-24 Durect Corp Flow regulator
EP1481705A1 (en) * 2003-05-27 2004-12-01 C.R.F. Societa' Consortile per Azioni A radiofrequency-controlled device for release / sampling of substances
US20040238769A1 (en) * 2003-05-27 2004-12-02 C.R.F. Societa Consortile Per Azioni Radiofrequency-controlled device for release/sampling of substances
US7086637B2 (en) 2003-05-27 2006-08-08 C.R.F. Societa Consortile Per Azioni Radiofrequency-controlled device for release/sampling of substances
US8221395B2 (en) 2004-03-02 2012-07-17 The Alfred E. Mann Foundation For Scientific Research Method and apparatus for automatically modifying delivery profile of drug delivery system
WO2005084273A3 (en) * 2004-03-02 2006-08-17 Medical Res Products A Inc Method and apparatus for automatically modifying delivery profile of drug delivry system
US20080177254A1 (en) * 2004-03-02 2008-07-24 Shelton Brian M Method and Apparatus for Automatically Modifying Delivery Profile of Drug Delivery System
US20050197649A1 (en) * 2004-03-02 2005-09-08 Medical Research Products-A, Inc. Method and apparatus for automatically modifying delivery profile of drug delivery system
US7347854B2 (en) * 2004-03-02 2008-03-25 Infusion Systems, Llc Method and apparatus for automatically modifying delivery profile of drug delivery system
WO2006077528A3 (en) * 2005-01-18 2007-03-01 Koninkl Philips Electronics Nv Electronically controlled capsule
WO2006077528A2 (en) * 2005-01-18 2006-07-27 Koninklijke Philips Electronics, N.V. Electronically controlled capsule
US20090306633A1 (en) * 2005-01-18 2009-12-10 Koninklijke Philips Electronics, N.V. Electronically controlled capsule
US8998884B2 (en) 2005-11-09 2015-04-07 The Invention Science Fund I, Llc Remote controlled in situ reaction method
US9028467B2 (en) 2005-11-09 2015-05-12 The Invention Science Fund I, Llc Osmotic pump with remotely controlled osmotic pressure generation
US9474712B2 (en) 2005-11-09 2016-10-25 Gearbox, Llc In situ reaction device
US8992511B2 (en) 2005-11-09 2015-03-31 The Invention Science Fund I, Llc Acoustically controlled substance delivery device
US9067047B2 (en) 2005-11-09 2015-06-30 The Invention Science Fund I, Llc Injectable controlled release fluid delivery system
US8968274B2 (en) 2005-11-09 2015-03-03 The Invention Science Fund I, Llc Acoustically controlled substance delivery device
US20100076415A1 (en) * 2005-11-09 2010-03-25 Searete Llc Remote control of substance delivery system
US8936590B2 (en) 2005-11-09 2015-01-20 The Invention Science Fund I, Llc Acoustically controlled reaction device
US8906000B2 (en) 2005-11-09 2014-12-09 The Invention Science Fund I, Llc Injectable controlled release fluid delivery system
GB2446099B (en) * 2005-11-09 2011-11-02 Searete Llc Osmotic pump with remotely controlled osmotic flow rate
US8882747B2 (en) 2005-11-09 2014-11-11 The Invention Science Fund I, Llc Substance delivery system
US8585684B2 (en) 2005-11-09 2013-11-19 The Invention Science Fund I, Llc Reaction device controlled by magnetic control signal
US9254256B2 (en) 2005-11-09 2016-02-09 The Invention Science Fund I, Llc Remote controlled in vivo reaction method
US8568388B2 (en) 2005-11-09 2013-10-29 The Invention Science Fund I, Llc Remote controlled in situ reaction device
US8172833B2 (en) 2005-11-09 2012-05-08 The Invention Science Fund I, Llc Remote control of substance delivery system
US8529551B2 (en) 2005-11-09 2013-09-10 The Invention Science Fund I, Llc Acoustically controlled substance delivery device
US8114065B2 (en) 2005-11-09 2012-02-14 The Invention Science Fund I, Llc Remote control of substance delivery system
US8617141B2 (en) 2005-11-09 2013-12-31 The Invention Science Fund I, Llc Remote controlled in situ reaction device
US8192390B2 (en) 2005-12-13 2012-06-05 The Invention Science Fund I, Llc Method and system for control of osmotic pump device
US20120289943A1 (en) * 2005-12-13 2012-11-15 Searete Llc Osmotic pump with remotely controlled osmotic flow rate
US8998886B2 (en) 2005-12-13 2015-04-07 The Invention Science Fund I, Llc Remote control of osmotic pump device
US8109923B2 (en) 2005-12-13 2012-02-07 The Invention Science Fund I, Llc Osmotic pump with remotely controlled osmotic pressure generation
US8273075B2 (en) 2005-12-13 2012-09-25 The Invention Science Fund I, Llc Osmotic pump with remotely controlled osmotic flow rate
US20100030185A1 (en) * 2006-01-18 2010-02-04 Searete Llc Remote controller for substance delivery system
US8273071B2 (en) 2006-01-18 2012-09-25 The Invention Science Fund I, Llc Remote controller for substance delivery system
US8367003B2 (en) 2006-03-09 2013-02-05 The Invention Science Fund I, Llc Acoustically controlled reaction device
US8349261B2 (en) 2006-03-09 2013-01-08 The Invention Science Fund, I, LLC Acoustically controlled reaction device
US8083710B2 (en) 2006-03-09 2011-12-27 The Invention Science Fund I, Llc Acoustically controlled substance delivery device
US20090005727A1 (en) * 2006-03-09 2009-01-01 Searete Llc Acoustically controlled substance delivery device
US20090162249A1 (en) * 2006-03-09 2009-06-25 Searete Llc Acoustically controlled reaction device
US7897113B2 (en) * 2006-07-17 2011-03-01 Industrial Technology Research Institute Fluidic devices and controlling methods thereof
US20080171342A1 (en) * 2006-07-17 2008-07-17 Industrial Technology Research Institute Fluidic devices and controlling methods thereof
ES2319147A1 (en) * 2007-03-30 2009-05-04 Universidad Politecnica De Madrid Microsystem TELEOPERATED with active chambers for chemical analysis.
GB2462779B (en) * 2007-05-25 2012-03-07 Searete Llc Injectable controlled release fluid delivery system
US20090259112A1 (en) * 2008-04-09 2009-10-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Sensors
US20090259214A1 (en) * 2008-04-09 2009-10-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Agent delivery device
US20110172525A1 (en) * 2008-12-05 2011-07-14 Neer Charles S Inductively Coupled Injector Faceplate
JP2016512992A (en) * 2013-02-28 2016-05-12 マイクロチップス バイオテック,インコーポレイテッド Implantable medical devices for minimally invasive insertion

Also Published As

Publication number Publication date Type
US6454759B2 (en) 2002-09-24 grant

Similar Documents

Publication Publication Date Title
US7216671B2 (en) Microfabricated elastomeric valve and pump systems
Shawgo et al. BioMEMS for drug delivery
US5207666A (en) Passive shuttle metering device for implantable drug delivery system
US6611707B1 (en) Microneedle drug delivery device
US5219278A (en) Micropump with improved priming
US6554822B1 (en) Microbolus infusion pump
US7988685B2 (en) Hydrogel compositions, devices, and microscale components
US4505710A (en) Implantable fluid dispensing system
US5391164A (en) Subcutaneous implantable multiple-agent delivery system
US7364568B2 (en) Microneedle transdermal transport device
US5895372A (en) Implantable dosaging system
US7367968B2 (en) Implantable pump with adjustable flow rate
US5368570A (en) Apparatus for infusing medical solutions
US5785688A (en) Fluid delivery apparatus and method
EP1403519A1 (en) Membrane pump with stretchable pump membrane
US20070066939A1 (en) Electrokinetic Infusion Pump System
US5643207A (en) Implantable techniques for infusing a therapeutic agent with endogenous bodily fluid
US20050197654A1 (en) Multiple section parenteral drug delivery apparatus
US20090227988A1 (en) Injectable controlled release fluid delivery system
US5618269A (en) Pressure-driven attachable topical fluid delivery system
US20050119618A1 (en) Hydraulically actuated pump for long duration medicament administration
US20080132842A1 (en) Plunger assembly for patient infusion device
US20030208184A1 (en) Implantable, refillable infusion device and spetum replacement kit
Ashraf et al. Micro electromechanical systems (MEMS) based microfluidic devices for biomedical applications
US6659982B2 (en) Micro infusion drug delivery device

Legal Events

Date Code Title Description
AS Assignment

Owner name: REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE, CALI

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KRULEVITCH, PETER A.;WANG, AMY;REEL/FRAME:011604/0187

Effective date: 20010226

AS Assignment

Owner name: ENERGY, U.S. DEPARTMENT OF, CALIFORNIA

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:CALIFORNIA, UNIVERSITY OF;REEL/FRAME:012484/0031

Effective date: 20010823

FPAY Fee payment

Year of fee payment: 4

AS Assignment

Owner name: LAWRENCE LIVERMORE NATIONAL SECURITY LLC, CALIFORN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THE REGENTS OF THE UNIVERSITY OF CALIFORNIA;REEL/FRAME:021217/0050

Effective date: 20080623

FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
FP Expired due to failure to pay maintenance fee

Effective date: 20140924